<DOC>
	<DOCNO>NCT02186626</DOCNO>
	<brief_summary>West Nile virus ( WNV ) consider emerge virus United States , infection lead severe illness old adult . This study evaluate safety immune response live West Nile virus vaccine ( WN/DEN4Δ30 ) prevention West Nile encephalitis adult 50 65 year old .</brief_summary>
	<brief_title>Evaluating Safety Immunogenicity Live Attenuated West Nile Virus Vaccine West Nile Encephalitis Adults 50 65 Years Age</brief_title>
	<detailed_description>WNV lead vector-borne cause viral encephalitis United States . Severe illness common old adult , population , virus cause hepatitis , meningitis , encephalitis lead paralysis , coma , death . WNV illness public health issue emerge disease United States . This study evaluate safety immunogenicity live attenuate West Nile/dengue chimeric virus vaccine ( WN/DEN4Δ30 ) prevention West Nile encephalitis adult 50 65 year old . This study enroll healthy adult , 50 65 year old , history previous flavivirus infection . Participants randomly assign receive WN/DEN4Δ30 vaccine placebo vaccine study entry ( Day 0 ) . At entry visit , participant undergo medical history review , physical examination , blood collection , vital sign measurement ; female participant also take pregnancy test . Participants receive assign vaccine , remain clinic 30 minute vaccination monitoring . Participants record temperature symptoms 3 time day 16 day vaccination . Additional study visit occur Days 3 , 6 , 8 , 10 , 12 , 14 , 16 , 21 , 28 , 56 , 90 , 150 . These visit may include study procedure occur entry visit . At study visit Day 180 , participant receive another dose assign vaccine . Additional study visit occur Days 183 , 186 , 188 , 190 , 192 , 194 , 196 , 201 , 208 , 236 , 270 , 360 . All study procedure second vaccination occur first vaccination .</detailed_description>
	<mesh_term>Encephalitis</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Adult male nonpregnant , nonbreastfeeding female 50 65 year age , inclusive . Children recruit enrol study safety consideration . Good general health , determine mean screen procedure Available duration trial Willingness participate study evidence sign informed consent form ( ICF ) Pregnancy , determine positive betahuman choriogonadotropin ( HCG ) test ( female ) Currently lactate breastfeed ( female ) Participant unwilling use reliable contraception method duration trial ( reliable method birth control include : pharmacologic contraceptive include oral , parenteral , transcutaneous delivery ; condom spermicide ; diaphragm spermicide ; surgical sterilization ; intrauterine device ; abstinence ; postmenopausal document least 1 year ) . All female participant consider childbearing potential except documented hysterectomy , tubal ligation , tubal coil ( least 3 month prior vaccination ) , postmenopausal least 1 year since last menstrual period . Evidence clinically significant neurologic , cardiac , pulmonary , hepatic , rheumatologic , autoimmune , renal disease history , physical examination , and/or laboratory study Behavioral , cognitive , psychiatric disease opinion investigator affect ability participant understand cooperate study protocol Screening laboratory value Grade 1 absolute neutrophil count ( ANC ) , alanine aminotransferase ( ALT ) , serum creatinine , define protocol Other condition opinion investigator would jeopardize safety right participant trial would render participant unable comply protocol Participant medical , occupational , family problem result alcohol illicit drug use past 12 month History severe allergic reaction anaphylaxis Severe asthma ( emergency room visit hospitalization within last 6 month ) Positive HIV1 serology screen confirmatory assay Positive hepatitis C virus ( HCV ) screen confirmatory assay Hepatitis B virus ( HBV ) infection , positive hepatitis B surface antigen ( HBsAg ) Any confirm suspected immunosuppressive immune modulate disorder ( e.g. , asplenia , lupus , rheumatoid arthritis , vasculitis , scleroderma , diabetes mellitus ) Chronic administration ( great equal 14 day ) steroid ( define prednisone equivalent great equal 10 mg per day ) , immunosuppressant , immunemodifying drug initiate 28day period postvaccination ( topical nasal steroid allow ) Receipt live vaccine within 28 day kill vaccine within 14 day prior vaccination anticipate receipt vaccine 28 day follow vaccination History surgical splenectomy Receipt blood product within past 3 month , include transfusion immunoglobulin , anticipate receipt blood product immunoglobulin 28 day follow vaccination History serologic evidence previous WNV infection flavivirus infection ( e.g. , yellow fever virus , St. Louis encephalitis virus , dengue virus ) Previous receipt yellow fever , WNV , dengue vaccine ( licensed investigational ) Receipt investigational agent past 28 day anticipation receipt investigational agent within 28 day follow vaccination Refusal allow storage specimens future research Inclusion Criteria Second Dose : Good general health , determine physical examination review medical history Available duration study , approximately 26 week second dose Ongoing willingness participate study Females : female participant childbearing potential willing use effective contraception duration trial . Reliable method contraception include : hormonal birth control , condom spermicide , diaphragm spermicide , surgical sterilization , intrauterine device , abstinence ( great 6 month since last sexual encounter ) . All female participant consider childbearing potential except documented hysterectomy , tubal ligation , tubal coil ( least 3 month prior vaccination ) , postmenopausal least 1 year since last menstrual period . Exclusion Criteria Second Dose : Anaphylaxis angioedema follow first dose vaccine Females : currently pregnant , determine positive betaHCG test , breastfeed Evidence clinically significant neurologic , cardiac , pulmonary , hepatic , rheumatologic , autoimmune , renal disease history , physical examination , and/or laboratory study Behavioral , cognitive , psychiatric disease opinion investigator affect ability participant understand cooperate requirement study protocol Any condition opinion investigator would jeopardize safety right participant trial would render participant unable comply protocol Any significant alcohol drug abuse past 12 month cause medical , occupational , family problem , indicate participant history History severe allergic reaction anaphylaxis Severe asthma ( emergency room visit hospitalization within last 6 month ) HIV infection , screen confirmatory assay HCV infection , screen confirmatory assay HBV infection , HBsAg screen Any confirm suspected immunosuppressive immune modulate disorder ( e.g. , asplenia , lupus , rheumatoid arthritis , vasculitis , scleroderma , diabetes mellitus ) Current use anticoagulant medication Chronic administration ( great equal 14 day ) steroid ( define prednisone equivalent great equal 10 mg per day ) , immunosuppressant , immunemodifying drug initiate 28day period postvaccination ( topical nasal steroid allow ) Receipt live vaccine within 28 day kill vaccine within 14 day prior vaccination anticipate receipt vaccine 28 day follow vaccination History surgical splenectomy Receipt blood product within past 3 month , include transfusion immunoglobulin anticipate receipt blood product immunoglobulin 28 day follow vaccination Receipt investigational agent 28 day vaccination anticipate within 28 day follow vaccination Refusal allow storage specimens future research</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>West Nile Virus , vaccine</keyword>
</DOC>